Cell Innovation Partners

Cell Innovation Partners operates as a venture capital firm dedicated to fostering advancements within the biotechnology sector. The firm specializes in identifying and investing in nascent companies focused on next-generation therapies, particularly within the expansive fields of regenerative medicine, stem cell research, and technologies involving pluripotent cells like iPS cells. Through strategic capital deployment, Cell Innovation Partners aims to accelerate the development of groundbreaking biological innovations.

The firm was founded in 2014 as a collaborative initiative, co-managed by established entities ReproCELL and Shinsei Corporate Investment. This partnership was forged with the explicit insight that significant opportunities existed in propelling the commercialization of novel biotechnologies, specifically those addressing critical needs in healthcare through cellular and regenerative approaches. Their combined expertise underpins the strategic direction of their investment activities.

Cell Innovation Partners primarily serves early-stage and growth-stage venture companies that are actively developing therapies and technologies rooted in cell innovation. Its long-term vision is to cultivate a portfolio of companies that will ultimately bring transformative regenerative and cellular medicines to market, thereby addressing unmet medical needs and shaping the future landscape of global healthcare and biotechnology.